Viewing Results for: Life Science
February 26th, 2013
We recently found ourselves in the following conversation: Client: We need to engage employees in our company’s new mission. We need your help with the execution of the communications campaign. We already have the positioning and messaging. The CEO wrote More
December 12th, 2012
Last spring, Kari and Tom Whitehead, feeling hopeless and out of options, decided to enroll their 7-year-old daughter, Emma, who was suffering from leukemia, into an experimental treatment program. Emma has miraculously emerged from the treatment free of cancer, and More
July 31st, 2012
In early April, TEDMED hosted a conference in which the sole purpose was to discuss the future of healthcare and medicine as researched and studied by experts and thought leaders from all over the world. We were excited to hear More
April 6th, 2012
Once a year, TEDMED hosts a conference where innovators and fresh thinkers from all over the globe come together to discuss the future of healthcare and medicine. We are pleased to share that Rebecca Onie, Co-founder and CEO of Health More
March 26th, 2012
The “Best Content” series brings you a handful of the most thought-provoking and informative articles related to life science branding and marketing published over the last quarter, broken down into bite-size pieces for your convenience. On March 1, Eye More
February 21st, 2012
Pharma companies are especially active when it comes to corporate social responsibility (CSR). According to The Foundation Center’s “Key Facts on Corporate Foundations” Report, the pharmaceutical industry held the second largest share of corporate foundation giving (at 15.2%) in 2009, More
November 3rd, 2011
Just check the last ten drugs approved by the FDA: most are the result of partnerships between small biotech companies and much larger pharmaceutical companies. The Wall Street Journal recently covered the partnership between Bristol-Myers Squibb Co. and a small More
November 3rd, 2011
The pharma industry is at a decisive inflection point. The New York Times reported in March that drug firms are likely to face billions of dollars in losses due to the pending expiration of numerous patents. Furthermore, the legitimacy of More